Endo has made a business decision to discontinue Sumavel DosePro (sumatriptan injection) 6mg/0.5mL. 

Sumavel DosePro was approved in 2009 for the acute treatment of migraine or cluster headaches as a needle-free delivery system supplied in prefilled pens. The 4mg/0.5mL formulation was previously discontinued in 2016; today’s decision affecting the 6mg/0.5mL formulation is also not related to the product’s quality, safety or efficacy.

Sumatriptan, a selective 5-HT1B/1D receptor agonist, presumably exerts therapeutic effects by binding to 5-HT1B/1D receptors located on intracranial blood vessels an sensory nerves of the trigeminal system.

The agonist effects are thought to result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.

Related Articles

Follow @ClinicalPainAdv

Reference

FDA drug shortages. Current and resolved drug shortages and discontinuations reported to FDA. FDA. Updated February 27, 2018. Accessed March 6, 2018.

This article originally appeared on MPR